Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
193
-
Total 13F shares, excl. options
-
67.9M
-
Shares change
-
+184K
-
Total reported value, excl. options
-
$3.56B
-
Value change
-
+$16.6M
-
Put/Call ratio
-
0.49
-
Number of buys
-
89
-
Number of sells
-
-83
-
Price
-
$52.34
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2021
238 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q4 2021.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 193 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67.9M shares
of 108M outstanding shares and own 63.03% of the company stock.
Largest 10 shareholders include FMR LLC (11M shares), WASATCH ADVISORS INC (8.24M shares), VANGUARD GROUP INC (6.88M shares), BlackRock Inc. (5.72M shares), Bellevue Group AG (3.63M shares), MARSHALL WACE, LLP (2.39M shares), LORD, ABBETT & CO. LLC (2.13M shares), STATE STREET CORP (1.52M shares), PICTET ASSET MANAGEMENT SA (1.45M shares), and TimesSquare Capital Management, LLC (1.34M shares).
This table shows the top 193 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.